Anti-VISTA antibodies and fragments, uses thereof, and methods of identifying same
Linda A. Snyder, Pottstown, PA (US); Gordon Powers, Malvern, PA (US); Enrique Zudaire Ubani, Ambler, PA (US); and Douglas Matthew Marvel, Lansdale, PA (US)
Assigned to JANSSEN PHARMACEUTICA NV, Beerse (BE)
Filed by JANSSEN PHARMACEUTICA NV, Beerse (BE)
Filed on May 20, 2021, as Appl. No. 17/325,792.
Application 17/325,792 is a division of application No. 15/481,410, filed on Apr. 6, 2017, granted, now 11,014,987.
Application 15/481,410 is a continuation in part of application No. 15/107,784, granted, now 10,273,301, issued on Apr. 30, 2019, previously published as PCT/IB2014/002868, filed on Dec. 22, 2014.
Claims priority of provisional application 62/319,605, filed on Apr. 7, 2016.
Claims priority of provisional application 62/085,086, filed on Nov. 26, 2014.
Claims priority of provisional application 61/920,695, filed on Dec. 24, 2013.
Prior Publication US 2021/0347896 A1, Nov. 11, 2021
1. A nucleic acid encoding an antibody or antigen-binding fragment thereof comprising an antigen binding region that binds to a V-domain Ig Suppressor of T cell Activation (VISTA), wherein the encoded antigen binding region of the antibody or antigen binding region comprises a VH domain comprising a VH CDR1 having the amino acid sequence of SEQ ID NO:25, a VH CDR2 having the amino acid sequence of SEQ ID NO:26 and a VH CDR3 having the amino acid sequence of SEQ ID NO:27, and which further comprises an antibody VL domain comprising a VL CDR1 having the amino acid sequence of SEQ ID NO:28, a VL CDR2 having the amino acid sequence of SEQ ID NO:29 and a VL CDR3 having the amino acid sequence of SEQ ID NO:30.